BAM15
Mitochondrial Uncoupling Agent
Small-molecule mitochondrial protonophore studied as a tissue-safe alternative to DNP for thermogenesis research. Available as 30 mg/mL or 50 mg/mL in 30 mL.
Fat Loss / Metabolic
Category
From $80.99
Price
Research
Grade
Price
From $80.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Published oral DIO mouse protocol: 50 mg/kg/day for 8 weeks produced significant fat mass reduction without core temperature elevation (Alexopoulos 2020). Solution format enables direct aliquoting into oral gavage or vehicle dilution for SC research routes. The 900mg total inventory supports approximately 50 days of 350g rodent dosing at 17mg/day.
BAM-15 (N⁵,N⁶-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is neither a peptide nor an incretin. It is a small-molecule mitochondrial protonophore — a next-generation mitochondrial uncoupler designed at the Kenyon lab to address the thermogenic safety issues that discontinued DNP (2,4-dinitrophenol). Where DNP's uncoupling activity extended to plasma membrane potentials — the mechanism behind its lethal hyperthermia — BAM-15 is selective for the inner mitochondrial membrane, which preserves the organ-protective ion gradient chemistry while still dissipating mitochondrial H+ flux as heat.
Specifications
| Product | BAM15 |
|---|---|
| Category | Fat Loss / Metabolic |
| Format | Lyophilized powder |
| Price | From $80.99 |
Mitochondrial Selectivity
What Separates BAM-15 From DNP
DNP uncouples across every lipid bilayer it touches — mitochondrial inner membrane and plasma membrane alike. Plasma membrane uncoupling is what drives the fatal hyperthermia that removed DNP from clinical use. BAM-15's molecular geometry concentrates its H+ shuttle activity selectively at mitochondrial inner membranes, dissipating ΔΨm without collapsing cellular ion gradients. That selectivity is the central design achievement of the Kenyon/Chipuk compound.
Solubility Math
Why the 30mg/mL Solution Matters
BAM-15 is a hydrophobic fluoroaromatic. Starting from lyophilized powder in aqueous vehicle typically loses 20-40% of the nominal mass to incomplete dissolution — and that lost material falls out of solution unpredictably across reconstituted batches. The pre-solubilized 30mg/mL format eliminates that variability: you know the concentration, you know the mass going into each experiment, you skip the overnight DMSO-vehicle dissolution step that lyophilized researchers plan around.
Alexopoulos 2020 Reference
Published Rodent DIO Data At This Concentration
Alexopoulos et al. (Nature Communications 2020) dosed DIO mice at 50 mg/kg/day BAM-15 by oral gavage for 8 weeks, measuring ~15% body weight reduction and marked visceral adipose loss without core temperature elevation. That paper is the reference protocol this 30mg/mL format maps directly onto — the concentration is literally the published working solution strength.
Reported Outcomes
Pre-solubilized 900mg total compound (30mg/mL × 30mL)
Mitochondrial-selective uncoupling — avoids DNP-class plasma-membrane toxicity
Fluoroaromatic oxadiazolopyrazine small molecule, not a peptide
30mg/mL is standard published research dosing concentration
Bypasses the hydrophobic-compound dissolution loss common with lyophilized BAM-15
Kenyon and Chipuk laboratory rodent-validated mechanism
Pairs Well With
Research Protocol
Published oral DIO mouse protocol: 50 mg/kg/day for 8 weeks produced significant fat mass reduction without core temperature elevation (Alexopoulos 2020). Solution format enables direct aliquoting into oral gavage or vehicle dilution for SC research routes. The 900mg total inventory supports approximately 50 days of 350g rodent dosing at 17mg/day.
BAM15 — FAQs
Related Fat Loss / Metabolic Research
View All
AOD-9604
Modified 16-residue C-terminal fragment of human growth hormone (177-191), engineered to retain lipolytic activity without the metabolic effects of full-length hGH. Available in 2 mg, 5 mg, and 10 mg.
